Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Major adverse cardiovascular events (MACE) in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A target trial emulation study

View Full Paper
Ask AI
Bookmark
Share

Authors

HDHenyah W. DardirSBSophia BaldermanAAAnjali S. Advani

Discussion

Loading...

Member takes

Overview

Target trial emulation shows second/third-generation TKIs increase major adverse cardiovascular events in chronic myeloid leukemia compared to imatinib.

Key Points

  • Second- and third-generation tyrosine kinase inhibitors were associated with a significantly increased composite MACE risk.
  • Composite MACE risk was 1.73 times higher in patients treated with second/third-generation TKIs compared to imatinib.
  • Analysis of registry data using propensity score matching included 10,462 eligible patients with chronic myeloid leukemia.
  • Findings highlight critical cardiovascular risk implications, particularly with prolonged treatment durations over five years.

Cite This Study

Dardir et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3c3https://doi.org/10.1182/blood-2025-4627
View Full Paper
Ask AI
Bookmark
Share